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Smmary Formestane is a selective inhibitor of oestrogen synthesis by aromatase enzymes and induces
disease regression in breast cancer patients. This phase II randomised study was carried out to determine
whether there were any differences in the effects of two different doses of formestane on oestradiol (E2) serum
levels and to evaluate the corresponding clinical activity in post-menopausal patients with positive or unknown
oestrogen receptor status pretreated or not for advanced disease. Furthermore, possible drug interference with
adrenal steroidogenesis was assessed by measuring 17-hydroxycorticosteroid (17-OHCS) urinary levels. A total
of 143 patients entered the study and were randomly assigned to receive formestane 250 mg (72 patients) or
formestane 500 mg (71 patients), both given i.m. every 2 weeks. In comparison with baseline, E2 serum levels
decreased by an average of 40%o after only 15 days and remained unchanged thereafter, with no difference
being observed between the two doses. The values of 17-OHCS remained unchanged during treatment in both
groups. Objective responses were 28% (19,'69) in the 250mg and 46% (31 /68) in the 500mg group. In
conclusion, the two formestane doses were equally effective in reducing E2 levels without affecting adrenal
function, and in inducing a considerable percentage of clinical responses.
Over the last 20 years. the activity and efficacy of endocrine
treatments in post-menopausal patients with advanced breast
cancer have been confirmed. The major aim of endocrine
treatment is to reduce the oestrogenic stimulation of tumoral
cell growth (Santen et al., 1990).
Aromatase enzymes play a key role in oestrogen biosyn-
thesis, which occurs not only in the ovaries, but also in
peripheral tissues, where circulating androgens are converted
to oestrone (El) and oestradiol (E2) by means of the process
known as aromatisation. As peripheral aromatisation in-
creases in post-menopausal women, becoming the main
source of oestrogens, aromatase inhibition currently re-
presents one of the major endocrine modalities for the treat-
ment of post-menopausal breast cancer patients (Lonning et
al., 1990; Santen, 1991; Johannessen et al., 1993).
Aminoglutethimide (AG), the first-generation aromatase
inhibitor, has generally been used as a second-line endocrine
treatment for advanced breast cancer, achieving an overall
response rate of about 20-25% (Lonning & Kvinnsland,
1988). However, its poor tolerability, and the fact that it also
inhibits other adrenal enzyme systems (Dexter et al., 1967;
Lipton & Santen, 1974), has stimulated the development of
other selective and better tolerated aromatase inhibitors. Fur-
thermore, the increasing use of tamoxifen (TMX) as adjuvant
therapy has also prompted research in this field because
aromatase inhibitors could theoretically be used as first-line
endocrine therapy in breast cancer patients failing to respond
to TMX.
Formestane (4-hydroxyandrostenedione, 4-OHA) has been
found to inhibit peripheral aromatisation, leading to a sig-
nificant decrease in serum E2 and El levels of respectively
58% and 47% (Reed et al., 1990).
This drug is a 'suicide inhibitor' in vitro because it not only
inhibits the aromatisation reaction, but also irreversibly inac-
tivates aromatase enzyme binding, an effect that appears to
be more pronounced than when AG is used. The immediate
advantage of using formestane is that patients do not need
corticoid replacement during therapy, because the drug only
inhibits aromatase enzymes without affecting cytochrome
P450-related enzymes (Schwarzel et al., 1973). Given the fact
that various doses of formestane are capable of reducing
plasma oestrogen levels (Dowsett et al., 1987; 1989; Brodie et
al., 1990), and are as effective as AG in causing tumour
regression (Coombes et al., 1984; Goss et al., 1986; Hoffken
et al., 1990; Pickles et al., 1990; Stein et al., 1990; Coombs et
al., 1992), there is no agreement as to the optimal dose to use
in clinical practice.
To this end, the present paper reports the results of a study
designed to evaluate the ability of two different formestane
doses to reduce E2 levels without affecting adrenal cortisol
synthesis, and presents clinical data relating to their anti-
tumour activity.
Patets and methods
Patient selection
A total of 143 consecutive patients with advanced breast
cancer were enrolled in this randomised Phase II trial carried
out at the Medical Oncology Division B of Milan's Istituto
Nazionale per lo Studio e la Cura dei Tumori.
The eligibility criteria were a diagnosis of advanced breast
cancer with measurable disease, post-menopausal status, and
ECOG-scale performance status of 0-2, an age of 75 years
or less and positive oestrogen receptor (ER) and/or pro-
gesterone receptor (PR) status assessed on the primary
tumour or metastases. Receptor levels were measured using
the dextran-coated charcoal method; ER and PR values of
respectively more than 10 and 25 fmol per mg of cytosol
protein were considered positive. If the receptor status was
unknown, a disease-free interval (DFI) of more than 2 years
was required.
Post-menopausal status was defined as follows: a period of
more than 1 year since last menstruation; bilateral oophorec-
tomy; drug-induced amenorrhoea for more than 2 years in
patients aged more than 50 years, with the presence of
follicle-stimulating hormone (FSH) and luteinising hormone
(LH) levels within the post-menopausal range in patients
younger than 50 years.
All of the patients had to have normal peripheral leucocyte
and platelet counts and no severely impaired liver and/or
renal function. Patients could have previously received
chemotherapy or hormonotherapy (either as adjuvant treat-
ment or for metastatic disease), but previous AG treatment
was not allowed. A iinimum 3 week washout period from
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anti-tumour and/or hormonal drugs such as corticosteroids
was considered mandatory before starting the therapy; the
washout period was prolonged to up to 6 weeks if dru in
depot formulation had previously been used.
Patients were excluded if they presented more than one-
third liver involvement, lung lymphangitic metastases, brain
metastases or rapidly progressive disease with a life expec-
tancy of less than 3 months. Patients with only osteoblastic
lesions or pleural effusion were consided ineligible. No
concomitant anti-cancer therapy was permitted, with the
exception of limited radiotherapy fields in the presece of
other evaluable lesions. Any concomitant corticosteroid treat-
ment was considered as an exclusion criterion.
Signs, symptoms and toxicity were evaluated at each
formestane administration according to WHO criteria (World
Health Organization, 1979). Anti-tumour resonse was
evaluated by means ofphysical examination, bone scan, chest
and skeletal rdiography, liver echography or computerised
tomographic scan, complete blood cell counts and blood
chemistry.
These examiations were performed at the beginning of the
study, after 2 months as a first evaluation, and every 3
months thereafter. Additional procedures were used when
necessairy.
In accordance with the guidelines of the local bioethics
committee, all of the patients gave their informed consent
before starting treatment.
Hormonal measurements
In each patient, the peripheral blood samples for E2
measurements (- 20 ml) were always taken at the same time
(between 08.30 and 11.00 h before formestane injections), on
the first and 15th day of therapy, and then at 1, 2, 3 and
6 months. In all cases, the samples obtained during therapy
were always drawn 2 weeks after the last injection. The blood
was collected at room temperature, allowed to clot, centri-
fuged at 3,000 r.p.m. and then stored at - 20'C until assay.
After extraction with diethylther, E2 serum levels were
measured by means of radioimmunoassay (RIA), the details
of which have been previously published (Trunet et at.,
1992). In brief, the RIA uses a speific oestradiol antibody
(which has a negligible cross-reaction with El) and '25I-
labelled oestradiol as tracer. The minimum deabe dose
was 3.7 pmol 1', and the within- and between-assay coef-
ficients of variation were respectively 11/% and 15%.
Overnight 12 h urine samples (08.00-20.00 h) for 17-
OHCS measurements were collected on the day before star-
ting therapy, and at 1, 2, 3 and 6 months. The patients were
instructed as to how to collect urine sampks, and each of
them was given a standard 11 plastic tube (Kartel, Milan,
Italy). In order to check that the patients had collected all of
their urine, they were asked to compete a personal card
indicating when and how many times it had been colected,
espeially during the night. On each examination day, the
patients had to return the tube and the card (which was
checked by nursing staff). Subsequently, the volume of urine
was measrd and a 20 ml sample was taken and kept frozen
(- 20C) until analysis. Urinary adrenal glucocorticoid
metabolite levels wer measured by means of gas chromato-
graphy (Murphy & West, 1966).
Treatment plan
The patients were randomised to receive fortnightly i.m.
formestane doses of either 250 or 500 mg, injected by nurses.
Providing no severe adverse events occurred, the treatment
was continued as long as there was no disease ogreon.
At the time of progression, subsequent treatment was given
according to the physician's judgement.
Criteria for tumour response andfollow-up
The patients were closely followed, and considrd evaluable
for response after the administation of at least four doses of
formestane.
Objective response (OR) was defined in accordance with
UICC criteria (Hayward et al., 1977); complete remission
(CR) was defined as the disappearance of all known disease
for a minimum of 1 month; partial remission (PR) as a
decrease of at kast 50% in the sum of the products of the
two largest perpendiclar diameters of all tumour masses for
at least 1 month; stable disease (SD) as a ess than 50%
decrease or a less than 25% increase in the size of the
measurable lesions; progressive disease (PD) as an increase of
at least 25% in the size of any tumour lesion or the
appearance of new lesions. In this study, the patients
classified as having stable disea had to have been stable for
at least 12 months. For bone disease, CR was defined as the
disappearance during treatment of all completely recacified
lytic bone metastases. In the presence of partal
recacification, the disease was considered as being in partial
remission. In no case was pain relief considered an objective
response.
In the case ofdrug discontinuation for progressive disease,
the patients were followed up every 2 months in order to
record their survival time.
Statisticalmethods
The randomisation list (blocks of ten patients for each of the
two treatments) was created using Fisher and Yates statistical
tables (Fisher & Yates, 1963). It was kept blinded in the
Italian Trials in Medical Oncology (ITMO) Data Manage-
ment Service, and the dose of formestane was disclosed to
the physian only at the beginning of treatment in each
patient.
The comparison between the baselin E2 levels in the two
treatment groups was performed using Student's t-test. The
effects of the two fomestane doses on E2 serm and urinary
17-OHCS levels were evahlated s ANOVA, with Dunnett's
test being used for multiple comparisons. The Stafistical
Analysis System (SAS, version 6.04) was used. For E2, the
computations were based on the natural logarithm of the
original measures in order to achieve normally distributed
data. Quantitative data are reported as mean ± standard
deviation (s.d.) or standard error of the mean (s.e.m). A
P-vahle of 0.05 was considered as significnt, and 95%
con intervals were also calulated. The comparison
between response rates according to the two diffet formest-
ane doses was performed by means of the chi-square test.
The duration of response was calulated from the time the
best overall resonse (CR + PR) became evident to the time
of progression.
In evaluable patients, the time to progression (TTP) was
defined as the period from the date of starting treatment to
the date ofprogresson. In all of the randomised patients, the
time to treatment failure (TTF) was defined as the period
from the date ofsarting treatment to the date ofwithdrawal
for any cause.
Suival time was defined as the period from the date of
starting treatment to the date of death. JTP, 1TTF and
survival time were analysed usng the Kaaplan-Meier method.
Ras
Patient characteristics
Between June 1989 and October 1991, 143 consecutive
patients were randomised to formestane 250 (72 patients) or
500mg (71 patients). Six patients were not evaluable for
clinical reonse because they were protocol violators (one
patient on 250 mg and two on 500mg), refused treatment for
reasons other than side-effects (two patients on 250mg) or
were lost to follow-up (one patient on 500mg). Nevertheless,
in accordance with the intention-to-treat approach, these six
patients were included in the analysis of TTF and overall
survival.
Table I shows the main characteristics of the evaluable
patients, approximately 60% of whom in each treatmentFORMESTANE IN ADVANCED BREAST CANCER 147
group had a DFI of 2 years or more. It is also worth noting
that 12 stage IV patients entered the study. In most of the
patients (44 on 250 mg and 37 on 500 mg), spontaneous
menopause had lasted for more than 5 years. Fifty-two of the
patients (24 on 250 mg and 28 on 500 mg) had not received
any previous treatment for advanced disease, while the others
had been pretreated with hormonotherapy (41 on 250 mg
and 34 on 500 mg) and/or chemotherapy (ten on 250 mg and
eight on 500 mg). Twenty-two patients on 250 mg and 15 on
500 mg had had more than one previous treatment for meta-
static disease.
Endocrine effects
Figures 1 and 2 show the behaviour of serum E2 and urinary
17-OHCS levels in the two treatment groups.
Serum E2 levels were measurable in 131 evaluable patients.
At the beginning of the study, the mean levels in the two
groups were similar: 21.98 pmol 1' (95% CI 24.14-19.82
pmol 1-1) in the 250mg group and 21.40pmol l-1 (95% CI
23.38-19.42pmo1-') in the 500mg group (P= 0.73,
Student's t-test). There was no difference in the trend of
mean serum E2 levels over time between the two groups
(P = 0.4123, ANOvA F-test for the 'time x group' interaction
term), whereas Dunnett's test showed a statistically
significant reduction from baseline levels at all treatment
assessment times.
Urinary 17-OHCS levels were measurable in 127 patients
(64 on 250 mg and 63 on 500 mg). The baseline levels were
similar in both groups: respectively 2.05 mg 12 h-' (95% CI,
1.9-2.2 mg 12 h-') and 1.88 mg 12 h-' (95% CI, 1.6-2.1 mg
12 h-'). After 6 months of treatment, there was no statistical
difference between the urinary 17-OHCS levels of the two
groups (P = 0.4079), the observed changes falling within the
normal range.
Response to therapy
Table II shows the response to treatment for each formestane
dose. Patients treated with 250 mg achieved a 28% response
rate versus 46% for the 500 mg group; this difference was
statistically significant (P= 0.026). The median duration of
response in both groups was 9 months, with a range of
2-40+ months in the 250mg group and 2-33+ months in
the 500 mg group. The median times to CR were respectively
6 and 5 months (5 and 3 months for PRs). The median
number of administered doses was 15 in the 250mg and 18
in the 500 mg group.
Most of the completely responding patients in both groups
(about 70%) had a DFI of more than 2 years, and were both
ER and PR positive. Three patients in each group had
visceral disease. In six patients (three in each group), a very
long time of treatment was necessary to achieve tumour
regression (an average of 13 months). The median duration
of CRs was 11.5 (250 mg) and 13 months (500 mg). Table III
shows drug efficacy in relation to disease sites, and it is worth
noting the high number of soft-tissue CRs (11/48 on 250 mg
and 16/56 on 500 mg). Visceral CRs (five on 250 mg and
seven on 500 mg) and bone CRs (three on 250 mg and two
on 500 mg) were achieved in both groups; among the visceral
lesions, those of the lung were the most responsive in all of
the treated patients. Table IV shows the response in relation
to major prognostic factors. The response rate was similar in
the patients aged more and less than 60 years in the 250 mg
group (OR 29%); better results were observed in the over-0
year-olds treated with 500 mg (OR 58% vs 34%). In the
500 mg group, better responses were also obtained in patients
who were both ER and PR positive (18/31, 58%) or who had
a PR level > 50 fmol mg-' protein (14/22, 64%). Four out of
ten stage IV patients responded to the 500 mg dose. When
formestane was given as first-line treatment for metastatic
Table I Main patient characteristics
No. ofpatients
250 mg SOO mg
Evaluabk
Median age (range) (years)
ER (fmolmg-')
10-50
>50
Unknown
PR (fmolmg-')
25-50
>50
Negative
Unknown
ER+PR+
DFI (years)
Absent
<2
.2
Spontaneous menopause
Oophorectomy
Drug-induced menopause
Prior hormonal therapy
Adjuvant
For metastatic disease
Prior chemotherapy
Adjuvant
For metastatic disease
Site of metastatic disease
Soft tissue
Viscera
Bone
Number of sites
2
>,2
69
59 (46-75)
24
34
11
10
21
14
24
31
2
22
45
50
13
6
12
41
24
10
38
33
36
35
34
68
60 (31-71)
28
27
13
8
22
18
20
32
10
18
40
44
16
8
14
34
22
8
41
25
46
26
42
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Table I Response to treatment
No. of patients
250mg 500 mg
Evaluable 69 68
Complete remission (%) 8 (12) 10 (15)
Partial remission 11 21
CR+PR (%) 19 (28) 31 (46)
Stable disease 4 1
Progressive disease 46 36
Table m Response related to disease site
250 mg 500mg
Disease No. of CR + PR No. of CR + PR
site sites (%) sites (%)
Soft tissue 48 16 (33) 56 32 (57)
Skin 21 6 23 14
Lymph nodes 22 8 26 14
Breast 5 2 7 4
Viscera 46 14 (30) 32 10 (31)
Liver 12 3 12 3
Lung 21 6 7 2
Pleural effusion 13 5 13 5
Bone 34 6 (18) 43 16 (37)
Table IV Response related to major prognostic factors
250mg 500 mg
CR + PR(%) CR + PR (%)
DFI (years)
Absent - 4 (40)
<2 7 (32) 5 (28)
>, 2 12 (27) 22 (55)
ER (fmol mg-')
10-50 8 (33) 12 (43)
> 50 8 (24) 14 (52)
Unknown 3 (27) 5 (38)
PR (fmolmg-')
25-50 1 (10) 4 (50)
>50 7 (33) 14 (64)
Negative 6 (43) 7 (39)
Unknown 5 (21) 6 (30)
ER+ PR+ 9 (29) 18 (58)
No. of disease sites
1 12 (34) 14 (54)
>, 2 7 (21) 17 (40)
Prior treatmente 11 (26) 18 (45)
4-OHA (first line) 8 (31) 13 (46)
'For metastatic disease.
disease, the overall response was similar: CRs were obtained
in four of the patients on 250mg (15%), and in six of the
patients on 500mg (21%).
Of the 39 patients in the 250 mg group and the 31 patients
in the 500 mg group, who had received TMX for advanced
disease, nine (23%) and 17 (55%) respectively responded to
formestane. If the responses to formestane are considered in
relation to the outcome of previous TMX treatment, the
TMX-responsive patients in the 250 mg group responded
better than those who were TMX resistant (OR 39% vs
13%); the same was true in the 500mg group (OR 77% vs
50%).
Figures 3 and 4 show TTP and overall survival. The
median TTP in the two groups was 8 (range 8-46) and 9
months (range 2-35); the median survival time was 30 (range
1-46) and 22 months (range 2-47). No differences in TTF
and TTP were observed between the two treatments.
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Tolerability
The local and systemic tolerability of both formestane doses
were satisfactory. A few patients complained of mild and
transient side-effects; none of them delayed any formestane
injection, with the exception of one patient in the 250mg
group who discontinued treatment because of recurrent
thrombophlebitis.
Mild asthenia was observed in seven patients in the 250 mg
and in six patients in the 500 mg group; one patient in the
250 mg group had grade 3 asthenia requiring concomitant
corticosteroid treatment. Hot flushes were reported by two
patients in each group; spotting appeared only in three
patients in the 250 mg group. Mild nausea and vomiting
occurred in four patients in the 250 mg and three patients in
the 500 mg group. In two cases (one in each group), grade 2
neutropenia was observed, but the relationship with the drug
is uncertain because both of the patients had bone involve-
ment and had also been heavily pretreated with radiotherapy.
Only three patients, two on 250 mg and one on 500 mg,
complained of local side-effects consisting of gluteal pain and
erythema.
The results of this study offormestane given every 2 weeks to
a large number of breast cancer patients confirm our
preliminary findings and extend the literature on aromatase
inhibitors (Bajetta et al., 1992).
The major endocrine effect of formestane has been shown
to be a significant reduction in plasma oestrogen levels,
mainly E2; unlike AG, the drug causes no change in adrenal
synthesis (Samojlik et al., 1977, 1978; Coombes et al., 1984;
Dowsett et al., 1987; Lonning et al., 1990). In this study,
irrespective of the dose, E2 serum levels decreased by an
average of 40% from baseline values after only 15 days and
remained unchanged thereafter, thus confirming the efficacy
of formestane as an aromatase inhibitor. It is interesting to
O-1 I I I I
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note that the 250 mg dose maintained the maximal decrease
in E2 levels throughout the 14 day period between drug
administrations. This result is in accordance with the obser-
vations of Dowsett et al. (1989), although they found that E2
suppression was more variable with 250mg than with 500 mg
and that the phenomenon of recovery occurred prior to
reaching steady-state drug conditions. In our opinion, the
most important reason for this is that our study population
was three times larger.
The action of formestane on the glhocorticid metabolic
pathway has been previously described by Pickles et al.
(1990), who found that, in patients treated fortnightly with
formestane 250mg i.m., there was a transient fall in serum
cortisol levels for 2 weeks, followed by a subsequent increase.
The changes rained within the normal daytime range. Our
data show that, irrespective of the dose, formestane had no
effect on the excretion of 17-OHCS during 6 months of
treatment, thus providing biochemical support for the drug's
previously reported absence of adrenal toxicity (Coombes et
al., 1984; Goss et al., 1986). This finding is accounted for by
the high degree of specificity of the drug, which has been
documented as inhibiting the aromatase complex without
endangering other enzymes (Brodie et al., 1981). The clinical
efficacy and the absence of serious side-effects reported in
preliminary trials with formestane has led to a number of
studies aimed at determining the lowest therapeutic dose,
route and scheduling which still achieve maximal E2 suppres-
sion. The demonstrable clinical efficacy and low incidence of
local side-effects has led to 250 mg i.m. every 2 weeks being
selected as the preferred dose (Coombes et al., 1984; Dowsett
et al., 1989; Stein et al., 1990; Coombes et al., 1992). To
verify these data, we studied the clinical effects of formestane
250 mg and 500 mg.
In our experience, formestane is an effective and well-
tolerated endocrine treatment for advanced breast cancer.
Although a previous paper has reported that 13% ofpatients
complained of local side-effects (Coombes et al., 1992), we
believe that the intramusular route is well tolerated because
such effects were experieced by only three of our patients.
Systemic side-effects were also mild and similar in the two
groups. The only patient with grade 3 asthenia had liver
disease, which probably accounts for the symptom.
Tumour regression was obtained in 28% of the patients
treated with 250mg, and in 46% of those treated with
500mg. There were no differences between the two doses as
far as median duration ofresponse or median 1TP, TTF and
overall survival are concered. It is not possible to draw any
definitive conclusion concerning the better clinical results
obtained with the higher dose, because the size of our study
population was caculated in order to detect an endocrino-
logical difference between the two doses and there was no
stratification of the main prognostic factors before ran-
domisation. The difference in response rate may be due to a
real improvement in drug activity, or to other unpredictable
factors. Neverthelss, the evidlently greater activity of the
higher dose represents an original finding which supports a
dose-clinil response effect for formestane and deserves
further cinial investigation. In this regard, a dose-
biological response effect has already been suggested by the
greater inhibition of the peripheral aromatisation of and-
rostenedione into oestrone observed with the 500 mg dose
(Jones et al., 1992).
Sequential treatment with formestane after TMX provided
satisfactory cinical results. As expected, better results were
observed in patients responsive to TMX, although a good
response was also achieved in those who were TMX resistant.
The responses observed in these latter patients suggest that at
least some TMX-resistant tumours remain sensitive to further
endocrine therapy, because the failure of TMX may be due
to various mechanisms (Johnston et al., 1992).
The 39% overall response of our patients receiving forme-
stane as first-line therapy is interesting. In a previous study,
we also found that a major benefit can be obtained in
patients who have not received medical treatment before
staring formestane therapy (Bajetta et al., 1993). The
significant response rate observed with formestane as first-
line treatment for metastatic disease supports the choice of
formestane in the treatment of patients who have progressed
to adjuvant therapy.
In conclusion, the results of the present study involving a
large number ofpatients show no differences between the two
formestane doses in terms of endocrine effects, and confirm
their efficacy and selectivity. Formestane appears to be very
promising in terms ofresponse rate and does not lead to any
important local or systemic side-effects. On the basis of these
encouraging findings, a multicentre trial involving patients at
first relapse, coordinated by the ITMO group, is currently
being carried out.
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